Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

BCL-2 inhibition and AML: can we best Darwin?

Michaelis LC.

Blood. 2020 Mar 12;135(11):781-782. doi: 10.1182/blood.2019004757. No abstract available.

PMID:
32163555
2.

Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.

Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN.

Biol Blood Marrow Transplant. 2020 Jan 23. pii: S1083-8791(20)30021-5. doi: 10.1016/j.bbmt.2020.01.010. [Epub ahead of print]

PMID:
31982543
3.

A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.

Lin TL, Newell LF, Stuart RK, Michaelis LC, Rubenstein E, Pentikis HS, Callahan T, Alvarez D, Liboiron BD, Mayer LD, Wang Q, Banerjee K, Louie AC.

Cancer Chemother Pharmacol. 2019 Jul;84(1):163-173. doi: 10.1007/s00280-019-03856-9. Epub 2019 May 16.

4.

Preface.

Michaelis LC.

Best Pract Res Clin Haematol. 2019 Mar;32(1):1-2. doi: 10.1016/j.beha.2019.02.010. Epub 2019 Feb 23. No abstract available.

PMID:
30927968
5.

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.

Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G.

Lancet Haematol. 2019 Apr;6(4):e194-e203. doi: 10.1016/S2352-3026(19)30030-4.

PMID:
30926081
6.

Venetoclax in AML: aiming for "just right".

Michaelis LC.

Blood. 2019 Jan 3;133(1):3-4. doi: 10.1182/blood-2018-11-883454. No abstract available.

PMID:
30606807
7.

Cytotoxic therapy in acute myeloid leukemia: not quite dead yet.

Michaelis LC.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):51-62. doi: 10.1182/asheducation-2018.1.51. Review.

8.

Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia.

Michaelis LC, Klepin HD, Walter RB.

Expert Opin Pharmacother. 2018 Jun;19(8):865-882. doi: 10.1080/14656566.2018.1465562. Epub 2018 Apr 26. Review.

PMID:
29697000
9.

Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).

Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR.

Leuk Res. 2018 Apr;67:17-20. doi: 10.1016/j.leukres.2018.01.021. Epub 2018 Jan 31.

10.

Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.

Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, Litzow MR, Stone RM, Erba HP.

Am J Hematol. 2018 Feb;93(2):E49-E52. doi: 10.1002/ajh.24980. Epub 2017 Dec 4. No abstract available.

11.

Current challenges in the management of essential thrombocythemia.

Kleman A, Singavi AK, Michaelis LC.

Clin Adv Hematol Oncol. 2017 Oct;15(10):773-783. Review.

PMID:
29040257
12.

Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis.

Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B.

Am J Hematol. 2017 Sep;92(9):E563-E565. doi: 10.1002/ajh.24825. Epub 2017 Jul 7. No abstract available.

13.

Risk stratification in myelofibrosis: the quest for simplification.

Michaelis LC.

Haematologica. 2017 Jan;102(1):2-3. doi: 10.3324/haematol.2016.158865. No abstract available.

14.

Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms.

Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC.

Bone Marrow Transplant. 2016 Apr;51(4):617-8. doi: 10.1038/bmt.2015.295. Epub 2016 Jan 4. No abstract available.

PMID:
26726940
15.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V.

Biol Blood Marrow Transplant. 2016 Mar;22(3):432-40. doi: 10.1016/j.bbmt.2015.10.005. Epub 2015 Oct 19.

16.

Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014.

Michaelis LC, Erba HP.

Curr Opin Hematol. 2015 Mar;22(2):108-15. doi: 10.1097/MOH.0000000000000120. Review.

PMID:
25603478
17.

Mechanisms of thrombogenesis in polycythemia vera.

Kroll MH, Michaelis LC, Verstovsek S.

Blood Rev. 2015 Jul;29(4):215-21. doi: 10.1016/j.blre.2014.12.002. Epub 2014 Dec 13. Review.

18.

Costs of care for lung and colon cancer patients receiving chemotherapy following FDA policy changes.

Stroupe KT, Tarlov E, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Durazo-Arvizu R, Hynes DM.

Support Care Cancer. 2014 Dec;22(12):3153-63. doi: 10.1007/s00520-014-2296-y. Epub 2014 Jun 10.

PMID:
24912857
19.

Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age.

Michaelis LC, Hamadani M, Hari PN.

Expert Rev Hematol. 2014 Jun;7(3):321-4. doi: 10.1586/17474086.2014.913978. Epub 2014 May 2.

PMID:
24785114
20.

Cutis verticis gyrata.

Walshauser MA, Birch NW, Michaelis LC.

Am J Med Sci. 2014 Aug;348(2):176. doi: 10.1097/MAJ.0b013e31827ad2e9. No abstract available.

PMID:
23328837
21.

Salvage second hematopoietic cell transplantation in myeloma.

Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P; Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research.

Biol Blood Marrow Transplant. 2013 May;19(5):760-6. doi: 10.1016/j.bbmt.2013.01.004. Epub 2013 Jan 5.

22.

Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changes.

Stroupe KT, Tarlov E, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Durazo-Arvizu R, Browning MM, Hynes DM.

Pharmacotherapy. 2012 Nov;32(11):988-97. doi: 10.1002/phar.1134. Epub 2012 Oct 26.

PMID:
23108695
23.

Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002-2008.

Tarlov E, Stroupe KT, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Browning MM, Hynes DM.

Support Care Cancer. 2012 Aug;20(8):1649-57. doi: 10.1007/s00520-011-1255-0. Epub 2011 Sep 20.

PMID:
21935718
25.

Measuring response in a post-RECIST world: from black and white to shades of grey.

Michaelis LC, Ratain MJ.

Nat Rev Cancer. 2006 May;6(5):409-14. Review.

PMID:
16633367
26.

Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?

Stadler WM, Michaelis LC, Ratain MJ.

J Clin Oncol. 2005 Nov 1;23(31):8124-5; author reply 8125-6. No abstract available.

PMID:
16258115

Supplemental Content

Loading ...
Support Center